{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T07:16:29Z","timestamp":1781853389848,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.virol.2023.02.005","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T08:34:15Z","timestamp":1676622855000},"page":"34-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Establishing an accurate and sensitive in vitro drug screening system for human adenovirus infection with human corneal cells"],"prefix":"10.1016","volume":"581","author":[{"given":"Mina","family":"Sasano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumi","family":"Kawaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-2752","authenticated-orcid":false,"given":"Eiich N.","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virol.2023.02.005_bib1","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/jps.24380","article-title":"Formulation and characterization of atropine sulfate in albumin-chitosan microparticles for in vivo ocular drug delivery","volume":"104","author":"Addo","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.virol.2023.02.005_bib2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/nchem.2308","article-title":"Use of a biosynthetic intermediate to explore the chemical diversity of pseudo-natural fungal polyketides","volume":"7","author":"Asai","year":"2015","journal-title":"Nat. Chem."},{"key":"10.1016\/j.virol.2023.02.005_bib3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/01.ico.0000170693.13326.fb","article-title":"Adenoviral keratoconjunctivitis in a tertiary care eye clinic","volume":"25","author":"Butt","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.virol.2023.02.005_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00003226-199503000-00010","article-title":"Adenovirus epithelial keratitis","volume":"14","author":"Chodosh","year":"1995","journal-title":"Cornea"},{"key":"10.1016\/j.virol.2023.02.005_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105034","article-title":"Emerging antiviral therapeutics for human adenovirus infection: recent developments and novel strategies","volume":"188","author":"Dodge","year":"2021","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2023.02.005_bib6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/oxfordjournals.epirev.a036304","article-title":"Epidemiology of epidemic keratoconjunctivitis","volume":"9","author":"Ford","year":"1987","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.virol.2023.02.005_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1248\/bpb.34.197","article-title":"Anti-adenovirus activities of shikonin, a component of Chinese herbal medicine in vitro","volume":"34","author":"Gao","year":"2011","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.virol.2023.02.005_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1556\/EuJMI.4.2014.1.2","article-title":"Human adenovirus: viral pathogen with increasing importance","volume":"4","author":"Ghebremedhin","year":"2014","journal-title":"Eur J Microbiol Immunol (Bp)"},{"key":"10.1016\/j.virol.2023.02.005_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0166-3542(91)90054-U","article-title":"Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2'-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro","volume":"16","author":"Gordon","year":"1991","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2023.02.005_bib10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.bbmt.2016.12.621","article-title":"Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled phase II trial","volume":"23","author":"Grimley","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.virol.2023.02.005_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.antiviral.2009.02.189","article-title":"Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naive patients","volume":"82","author":"Hachiya","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2023.02.005_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01569-21","article-title":"Sensitivity of human mastadenovirus, the causal agent of pharyngoconjunctival fever, epidemic keratoconjunctivitis, and hemorrhagic cystitis in immunocompromised individuals, to brincidofovir","volume":"10","author":"Hanaoka","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.virol.2023.02.005_bib13","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1086\/426831","article-title":"Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro","volume":"191","author":"Hartline","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virol.2023.02.005_bib14","first-page":"315","article-title":"Antiadenoviral effects of ganciclovir in types inducing keratoconjunctivitis by quantitative polymerase chain reaction methods","volume":"8","author":"Huang","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.virol.2023.02.005_bib15","first-page":"786","article-title":"[Evaluation of antiviral agents for adenovirus using the MTT method in vitro]","volume":"104","author":"Kaneko","year":"2000","journal-title":"Nippon. Ganka Gakkai Zasshi"},{"key":"10.1016\/j.virol.2023.02.005_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/2040206620916571","article-title":"In vitro anti-adenoviral activities of ethanol extract, fractions, and main phenolic compounds of pomegranate (Punica granatum L.) peel","volume":"28","author":"Karimi","year":"2020","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.virol.2023.02.005_bib17","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1128\/jvi.66.4.2232-2239.1992","article-title":"Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene","volume":"66","author":"Kimpton","year":"1992","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2023.02.005_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0166-3542(96)06966-5","article-title":"Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method","volume":"31","author":"Kodama","year":"1996","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2023.02.005_bib19","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1128\/AAC.45.5.1539-1546.2001","article-title":"4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro","volume":"45","author":"Kodama","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2023.02.005_bib20","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.ophtha.2018.02.016","article-title":"Determinants of outcomes of adenoviral keratoconjunctivitis","volume":"125","author":"Lee","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.virol.2023.02.005_bib21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/rmv.589","article-title":"Clinical features and treatment of adenovirus infections","volume":"18","author":"Lenaerts","year":"2008","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.virol.2023.02.005_bib22","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1128\/AAC.49.11.4689-4699.2005","article-title":"Mouse adenovirus type 1 infection in SCID mice: an experimental model for antiviral therapy of systemic adenovirus infections","volume":"49","author":"Lenaerts","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2023.02.005_bib23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41598-021-04199-3","article-title":"Comparison of cytotoxicity effects induced by four different types of nanoparticles in human corneal and conjunctival epithelial cells","volume":"12","author":"Li","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virol.2023.02.005_bib24","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.exer.2006.11.014","article-title":"Establishment of a corneal epithelial cell line spontaneously derived from human limbal cells","volume":"84","author":"Liu","year":"2007","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.virol.2023.02.005_bib25","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0166-3542(97)01029-2","article-title":"Inhibitory activity of 3'-fluoro-2' deoxythymidine and related nucleoside analogues against adenoviruses in vitro","volume":"34","author":"Mentel","year":"1997","journal-title":"Antivir. Res."},{"key":"10.1016\/j.virol.2023.02.005_bib26","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1128\/AAC.49.3.1010-1016.2005","article-title":"Antiadenovirus activities of several classes of nucleoside and nucleotide analogues","volume":"49","author":"Naesens","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.virol.2023.02.005_bib27","doi-asserted-by":"crossref","DOI":"10.1177\/2040206620921319","article-title":"Application of human lymphoid cells for the evaluation of antivirals against human adenovirus type 19: zalcitabine has superior activity compared to cidofovir","volume":"28","author":"Nakagawara","year":"2020","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.virol.2023.02.005_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01843-21","article-title":"Antiviral activity and resistance profile of the novel HIV-1 non-catalytic site integrase inhibitor JTP-0157602","volume":"96","author":"Ohata","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2023.02.005_bib29","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1167\/iovs.08-3286","article-title":"The in vitro and in vivo evaluation of ddC as a topical antiviral for ocular adenovirus infections","volume":"50","author":"Romanowski","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.virol.2023.02.005_bib30","doi-asserted-by":"crossref","first-page":"39471","DOI":"10.1074\/jbc.M110.145789","article-title":"Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors","volume":"285","author":"Shimura","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virol.2023.02.005_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02019-16","article-title":"Human adenovirus type 37 Uses alpha(V)beta(1) and alpha(3)beta(1) integrins for infection of human corneal cells","volume":"91","author":"Storm","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.virol.2023.02.005_bib32","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00417-006-0523-z","article-title":"Anti-adenoviral effect of anti-HIV agents in vitro in serotypes inducing keratoconjunctivitis","volume":"245","author":"Uchio","year":"2007","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.virol.2023.02.005_bib33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.antiviral.2009.02.002","article-title":"Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide","volume":"82","author":"Ueno","year":"2009","journal-title":"Antivir. Res."}],"container-title":["Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682223000284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0042682223000284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:58:17Z","timestamp":1758589097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0042682223000284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":33,"alternative-id":["S0042682223000284"],"URL":"https:\/\/doi.org\/10.1016\/j.virol.2023.02.005","relation":{},"ISSN":["0042-6822"],"issn-type":[{"value":"0042-6822","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Establishing an accurate and sensitive in vitro drug screening system for human adenovirus infection with human corneal cells","name":"articletitle","label":"Article Title"},{"value":"Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virol.2023.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}